SPRING HOUSE, PA — Johnson & Johnson (NYSE: JNJ) announced recently that its oral psoriasis treatment ICOTYDE (icotrokinra) achieved sustained skin clearance rates through 52 weeks in Phase 3 clinical trials, with results presented at the American Academy of Dermatology Annual Meeting.
The data come from the ICONIC-ADVANCE 1 and 2 and ICONIC-LEAD studies, which evaluated the drug in patients with moderate-to-severe plaque psoriasis.
In the ADVANCE trials, the proportion of patients achieving complete skin clearance increased between Week 24 and Week 52, rising from 41 percent to 49 percent in one study and from 33 percent to 48 percent in the other.
Patients who switched from placebo to ICOTYDE at Week 16 reached similar clearance rates by Week 52, at 50 percent and 43 percent in the respective trials.
Johnson & Johnson said no new safety signals were identified through 52 weeks, and the adverse event profile remained consistent with earlier trial periods.
In the ICONIC-LEAD study, nearly 60 percent of adolescent patients treated with ICOTYDE achieved completely clear skin at Week 52.
Linda Stein Gold, a clinical investigator in the ADVANCE studies, said the results show continued treatment effects over one year.
“The results from one-year studies show encouraging outcomes for patients as they navigate this chronic condition,” she said.
Jennifer Soung, an investigator in the ICONIC-LEAD study, said the treatment expands options for younger patients.
“For the first time, patients 12 and older have access to a novel therapy capable of delivering sustained skin clearance,” Soung said.
ICOTYDE is an oral therapy designed to block the IL-23 receptor, a component of the inflammatory pathway associated with plaque psoriasis.
The drug is approved in the United States for adults and pediatric patients age 12 and older who weigh at least 40 kilograms and are candidates for systemic therapy or phototherapy.
The ICONIC clinical program includes multiple Phase 3 trials evaluating the drug against placebo and other treatments, including deucravacitinib and ustekinumab.
Additional studies are underway to assess ICOTYDE in psoriatic arthritis, ulcerative colitis and Crohn’s disease.
Plaque psoriasis is a chronic immune-mediated condition affecting an estimated 8 million people in the United States and more than 125 million worldwide, according to the company.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.